

***Helicobacter pylori* gastritis, a presequence to coronary plaque**

Shrikant C. Raut,¹ Vinayak W. Patil,¹ Shubhangi M. Dalvi,¹ Girish D. Bakhshi²

¹Department of Biochemistry;

²Department of Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai, India

Abstract

Helicobacter pylori are considered the most common human pathogen colonizing gastric mucosa. Gastritis with or without *H. pylori* infection is associated with increase in levels of homocysteine and high-sensitivity C-reactive protein (hs-CRP) but a more pronounced increase is noted in gastritis with *H. pylori* infection. Increasing level of homocysteine, due to decreased absorption of vitamin B₁₂ and folic acid, together with increased CRP levels in gastritis with *H. pylori* infection may be the earliest event in the process of atherosclerosis and plaque formation. Retrospective study conducted at tertiary care hospital in Mumbai by Department of Biochemistry in association with Department of Surgery. Eighty patients who underwent gastroscopy in view of gastritis were subjected to rapid urease test for diagnosis of *H. pylori* infection. Vitamin B₁₂, folic acid, homocysteine and hs-CRP were analyzed using chemiluminescence immuno assay. Student's t-test, Pearson's correlation and linear regression used for statistical analysis.

Patients with *H. pylori* gastritis had significantly lower levels of vitamin B₁₂ (271.6±101.3 vs 390.6±176.7 pg/mL; P=0.0005), as well as higher levels of homocysteine (17.4±7.4 vs 13.8±7.8 μmol/L; P=0.037) and hs-CRP (2.5±2.9 vs 1.2±1.1 mg/L; P=0.017), than in patients without *H. pylori* gastritis. However, folic acid showed (8.9±3.2 vs 10.0±3.6 ng/mL; P=0.171) no significant difference.

Elevated homocysteine and hs-CRP in *H. pylori* gastritis may independently induce endothelial dysfunction, leading to cardiovascular pathology.

Introduction

Helicobacter pylori are gram-negative, spiral shaped bacteria, that commonly and efficiently colonize the human gastric mucosa.¹ They are associated with wide spectrum of gastroin-

testinal disorders like, chronic active gastritis (predominantly antral gastritis), peptic ulcer disease, gastric mucosa associated lymphoid tissue lymphoma and gastric adenocarcinoma.²

Recent studies indicate a possible correlation between *H. pylori* infection and coronary heart disease.^{3,4} An intriguing hypothesis postulates that the gastric damage induced by *H. pylori* infection may affect atherosclerotic processes via increased serum homocysteine levels.⁵ Accumulation of homocysteine has been found toxic to endothelial cells and a risk factor for atherosclerosis.⁶ Hyperhomocysteinemia secondary to impaired absorption of folic acid and vitamin B₁₂ might be the link between *H. pylori* infection and coronary heart disease.

C-reactive protein (CRP) is an acute-phase reactant, identified as a marker of inflammation as well as an independent risk factor for cardiovascular diseases.⁷ Assay of serum levels of CRP using high-sensitivity assay (hs-CRP) can detect subclinical inflammatory status, which may reflect vascular inflammation.^{7,8}

Seroepidemiologic studies have demonstrated that atherosclerosis is associated with several infectious pathogens, including cytomegalovirus,⁹ *H. pylori*,¹⁰ and *C. pneumonia*.¹¹ If *H. pylori* has effects on the function of vascular endothelial cells, apart from homocysteine, serum CRP could be the other molecule to connect both. The pro-inflammatory cytokines produced due to stimulation by *H. pylori* infection regulate the production of CRP, which may create a pro-coagulant environment in the vascular endothelium thus forming a presequence to coronary plaque.¹²

The present study was conducted to compare the serum levels of vitamin B₁₂, folic acid, homocysteine and hs-CRP in gastritis with and without *H. pylori*, irrespective of staging of gastritis or presence or absence of gastric atrophy, so as to evaluate the cardiovascular risk imposed by the mere presence or absence of *H. pylori* infection in patients suffering from gastritis.

Materials and Methods

This study was conducted at Department of Biochemistry in collaboration with Department of Surgery, at a tertiary care hospital in Mumbai. Ethical committee approval was taken from the Institutional Review Board of the hospital and patients enrolled in the study consented for the same. The SPSS software (IBM Corp., Armonk, NY, USA) was used, t-test applied, Pearson's correlation and linear regression analysis was used to study correlation between the biomarkers, P-value less than 0.05 were considered to be

Correspondence: Shrikant C. Raut, 5/501 Mangalmurti Annexe, S.K. Bole Road, Agar Bazar, Dadar(W), Mumbai-400028, Maharashtra, India. Tel.: 9757109846. E-mail: dr.shrikantraut@yahoo.in

Key words: *Helicobacter pylori*, cardiovascular disease, homocysteine, C-reactive protein, vitamin B12, chemiluminescence.

Conflict of interest: the authors declare no potential conflict of interest.

Contributions: SCR, VWP, SMD, GDB, manuscript concept and design, definition of intellectual content, manuscript editing; SCR, literature search, statistical analysis and guarantor; SCR, GDB, data acquisition; SCR, SMD, data analysis, manuscript preparation; VWP, SMD, GDB, manuscript review.

Received for publication: 14 October 2014.

Revision received: 19 January 2015.

Accepted for publication: 2 February 2015.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright S.C. Raut et al., 2015
Licensee PAGEPress, Italy
Clinics and Practice 2015; 5:717
doi:10.4081/cp.2015.717

statistically significant. Patients in the age group 20-60 years of either sex, suspected of gastritis having one or more symptoms like, epigastric pain or burning, abdominal bloating, regurgitation, altered bowel habits, who attended the surgery clinic in our hospital between January to March 2013 were selected. On confirmation of gastritis by endoscopy, biopsy was taken from the gastric antrum to diagnose the presence of *H. pylori* infection with rapid urease test. Patients with renal or liver diseases, with a recent history of *H. pylori* eradication therapy (six months prior to the study), taking vitamin B₁₂ and folic acid supplements or drugs that affect their serum levels, with history or presence of other causes of vitamin malabsorption and pregnant women were excluded. A total of 80 patients (40 with *H. pylori* positive gastritis and 40 with *H. pylori* negative gastritis), who met these criteria were selected and subjected to blood investigations on fully automated enzyme amplified chemiluminescent immuno assay based Immulite 1000 analyzer by using commercial kits from Siemens Medical Solutions Diagnostics (Los Angeles, CA, USA).

H. pylori infection was diagnosed by Pylo-dry test (manufactured and marketed by Halifax Research Laboratories, Kolkata, India) which is a rapid urease test.

Procedure for rapid urease test

The procedure for rapid urease test was performed by following these steps:

- Patients subjected to upper gastrointestinal endoscopy (nil by mouth for six to eight hours) were sprayed with lidocaine topical aerosol (LOX 10% spray) for local anesthesia and a flexible, fiber-optic, endoscope [PENTAX EG – 2770K (2.8)] was maneuvered into the stomach.

- A gastric mucosal biopsy was taken from the pyloric antrum after confirmation of gastritis. The biopsy specimen was transferred from the biopsy forceps onto the exposed yellow media of the Pylo-dry test kit, after pulling the sticker of the kit.

- One drop of distilled water was added onto the yellow media containing the biopsy specimen and covering sticker was placed back as before.

- Urease enzyme of *H. pylori*, if present, reacts with urea of the media and changes the color from yellow to red or pink altering the pH to make it alkaline.

- The color change from yellow to red or pink was observed at 15 min interval for one hour and 30 min interval for the next hour.¹³

- The change in the color of the media from yellow to red or pink was taken as a positive test. Patients were then categorized into *H. pylori* positive gastritis and *H. pylori* negative gastritis.

- The patients who were found rapid urease test positive were prescribed anti *H. pylori* treatment.

Observations and Results

The mean age of patients with gastritis was

39.56±10.29 years (range 20-60 years), whereas, the mean age of patients with *H. pylori* positive gastritis was 39.12±10.89 years and that of *H. pylori* negative gastritis was 40±9.77 years. There was no significant difference in gender between *H. pylori* positive and negative gastritis (Table 1).

Serum vitamin B₁₂ levels were significantly lower and serum homocysteine and hs-CRP levels were significantly higher in patients with *H. pylori* positive gastritis than in those with *H. pylori* negative gastritis, whereas, there was no significant difference between mean serum levels of folic acid in *H. pylori* positive gastritis and *H. pylori* negative gastritis (Table 2).

Serum homocysteine was found to have a significant negative correlation with serum vitamin B₁₂ (Figure 1), and it showed a nega-

tive but not a significant correlation with folic acid (Figure 2) in *H. pylori* positive gastritis.

The serum hs-CRP levels in *H. pylori* positive gastritis and *H. pylori* negative gastritis were used to stratify patients into various levels of cardiovascular risk (Tables 3¹⁴ and 4).

Table 4 depicts that 55 % of patients with *H. pylori* positive gastritis had intermediate to high cardiovascular risk, whereas only 35% of patients with *H. pylori* negative gastritis had intermediate to high cardiovascular risk.

Discussion

It is well known that *H. pylori* infection is commonly associated with chronic active gastritis and peptic ulcer disease. The infection is

Table 1. Sex wise distribution of patients with type of gastritis.

Patient group	Sex		Total	P value
	Male	Female		
<i>H. pylori</i> positive gastritis n=40 (%)	29 (72.5)	11 (27.5)	40 (100)	0.469
<i>H. pylori</i> negative gastritis n=40 (%)	26 (55)	14 (35)	40 (100)	
Total	55 (68.8)	25 (31.2)	80 (100)	

Pearson Chi-Square value=0.524.

Table 2. Vitamin B₁₂, folic acid, homocysteine and high-sensitivity C-reactive protein levels in *Helicobacter pylori* positive and *H. pylori* negative gastritis.

Parameters	<i>H. pylori</i> positive gastritis	<i>H. pylori</i> negative gastritis	P value
Vitamin B ₁₂ (pg/mL)	271.6±101.3	390.6±176.7	0.0005**
Folic acid (ng/mL)	9.0±3.2	10±3.6	0.172
Homocysteine (µmol/L)	17.4±7.4	13.8±7.8	0.037*
hs-CRP (mg/L)	2.5±2.9	1.2±1.1	0.017*

**P≤0.001, highly significant; *P≤0.05, significant, values in mean±standard deviation. hs-CRP, high-sensitivity C-reactive protein.




Figure 1. Correlation between serum homocysteine and vitamin B₁₂ in *Helicobacter pylori* positive gastritis. r, Pearson's correlation coefficient.




Figure 2. Correlation of serum homocysteine and folic acid in *Helicobacter pylori* positive gastritis. r, Pearson's correlation coefficient.

Table 3. Cardiovascular risk stratification by high-sensitivity C-reactive protein value.

hs-CRP (mg/L)	Cardiovascular risk
< 1	Low
1-3	Intermediate/average
>3	High

hs-CRP, high-sensitivity C-reactive protein.

widespread in developing nations, where prevalence is believed to be more than 80% among middle-aged adults, whereas it is considerably lower in industrialized countries, with 20% to 50% of the population infected.¹⁵ The prevalence of *H. pylori* infection in India is upto 80%.¹⁶

In the present study, serum vitamin B₁₂ levels were significantly lower in patients with *H. pylori* positive gastritis as compared to those without. Whereas, folic acid levels showed no significant difference between the two groups. A similar study on 132 patients with functional dyspepsia also found an insignificant difference in folate levels between *H. pylori* positive and negative gastritis patients.¹⁷ It is an established fact that chronic *H. pylori* infection produces atrophic gastritis.¹⁸ Tamura *et al.*¹⁹ conducted a study on 93 patients who underwent coronary arteriography and suggested that chronic atrophic gastritis due to *H. pylori* infection decreases plasma vitamin B₁₂ and folic acid level there by increasing the circulating homocysteine levels.

Vitamin B₁₂ and folic acid malabsorption in gastric mucosal atrophy due to *H. pylori* infection may be due to, hypochlorhydria failing to split vitamin B₁₂ from food binders and its subsequent transfer to R-binder (haptocorrin) in the stomach,²⁰ or decreased secretion of ascorbic acid and secretory dysfunction of the intrinsic factor.^{21,22} A study on 145 dyspeptic patients also provided a strong evidence that, even in absence of gastric mucosal atrophy in *H. pylori* positive group, the cobalamin deficiency as a consequence of food cobalamin malabsorption is due to consumption of vitamin itself by *H. pylori* or effects of the infection (inflammation and related factors).²³

Present study demonstrates significantly higher circulating homocysteine levels in *H. pylori* positive group as compared to the negative group. It also depicts a good negative and significant correlation between homocysteine and vitamin B₁₂ and negative and insignificant correlation between homocysteine and folic acid in *H. pylori* positive group. These results to some extent support the hypothesis that *H. pylori* gastritis leads to decreased circulating vitamin B₁₂,

Table 4. Cardiovascular risk stratification of patients with *Helicobacter pylori* positive and negative gastritis with serum high-sensitivity C-reactive protein levels.

hs-CRP levels	<i>H. pylori</i> positive gastritis n=40 (%)	<i>H. pylori</i> negative gastritis n=40 (%)
<1 mg/L (low CVS risk)	18 (45)	26 (65)
1-3 mg/L (intermediate CVS risk)	11 (27.5)	07 (17.5)
>3 mg/L (high CVS risk)	11 (27.5)	07 (17.5)
Total	40 (100)	40 (100)

hs-CRP, high-sensitivity C-reactive protein; CVS, cardiovascular.

thereby increasing circulating homocysteine levels. Homocysteine has been shown to contribute to the development of coronary artery disease²⁴⁻³⁰ by causing direct endothelial damage,³¹⁻³³ affecting platelet function, coagulation factors^{34,35} and promoting oxidation of low density lipoproteins,³⁶ thereby, responsible for the development of atherosclerosis in the setting of chronic *H. pylori* infection.

A large number of studies have shown the pivotal role of inflammation in progression of atherosclerosis, hs-CRP is one such marker which may also play a role in formation and worsening the plaque by directly and indirectly activating inflammation and cytotoxicity.³⁷⁻³⁹ Several mechanisms by which CRP can promote a pro-atherogenic environment in endothelial cells have been suggested.⁴⁰

Significant association between *H. pylori* infection and serum CRP has been noted.^{12,41} Our study not only demonstrated significantly higher levels of hs-CRP in gastritis with *H. pylori* as compared to that without, but also noted that, 55% of patients with *H. pylori* positive gastritis had serum levels of hs-CRP in intermediate to high cardiovascular risk range as compared to only 35% in *H. pylori* negative gastritis.

A pro-atherogenic, pro-coagulant and pro-inflammatory environment is thus created both by elevated homocysteine and hs-CRP levels, suggesting a possible presequence to coronary plaque in *H. pylori* gastritis.

Conclusions

Our study, *H. pylori* gastritis not only depicts elevated serum homocysteine levels due to reduced serum vitamin B₁₂ levels, but also, an elevated serum hs-CRP level. Homocysteine and hs-CRP are said to exert toxic effects on vascular endothelial cells via independent mechanisms. They could thus be forming the possible link between *H. pylori* gastritis and coronary heart disease.

References

- Moreno Y, Piqueres P, Alonso JL, et al. Survival and viability of *Helicobacter pylori* after inoculation into chlorinated drinking water. *Water Res* 2007;41:3490-6.
- Farinha P, Gascoyne RD. *Helicobacter pylori* and MALT lymphoma. *Gastroenterology* 2005;128:1579-605.
- Mendall MA, Goggin PM, Molineaux N, et al. Relation of *Helicobacter pylori* infection and coronary heart disease. *Br Heart J* 1994;71:437-9.
- Patel P, Mendall MA, Carrington D, et al. Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections with coronary disease and cardiovascular risk factors. *BMJ* 1995;311:711-4.
- Sung JJ, Sanderson JE. Hyperhomocysteinemia, *Helicobacter pylori*, and coronary heart disease. *Heart* 1996;76:305-7.
- Markle HV. Coronary artery disease associated with *Helicobacter pylori* infection is at least partially due to inadequate folate status. *Med Hypotheses* 1997;49:289-92.
- Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular diseases; risk marker of pathogen. *Int J Cardiol* 2006;106:291-7.
- Singh SK, Suresh MV, Voleti B, Agrawal A. The connection between C-reactive protein and the atherosclerosis. *Am Med* 2008;40:110-20.
- Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. *N Engl J Med* 1996;335:624-30.
- Strachan DP, Mendall MA, Carrington D, et al. Relation of *Helicobacter pylori* infection to 13 year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study. *Circulation* 1998;98:1286-90.
- Boman J, Hammerschlag MR. *Chlamydia pneumoniae* and atherosclerosis: critical assessment of diagnostic methods and rel-

- evance to treatment studies. *Clin Microbiol Rev* 2002;15:1-20.
12. Ishida Y, Suzuki K, Taki K, et al. Significant association between *Helicobacter pylori* infection and serum C-reactive protein. *Int J Med Sci* 2008;5:224-9.
 13. Pande PR, Karki B, Pande R, Khatri R. Evaluation of locally made rapid urease test for diagnosis of *Helicobacter pylori*. *Postgrad Med J NAMS* 2009;9:50-3.
 14. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003;107:499-511.
 15. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002;347:1175-86.
 16. Lunet N, Barros H. *Helicobacter pylori* infection and gastric cancer: facing the enigmas. *Int J Cancer* 2003;106:953-60.
 17. Rasool S, Abid S, Iqbal MP, et al. Relationship between vitamin B 12, folate and homocysteine levels and *H. Pylori* infection in patients with functional dyspepsia: a cross-section study. *BMC Res Notes* 2012;5:206.
 18. Blaser MJ. *Helicobacter pylori*: its role in disease. *Clin Infect Dis* 1992;15:386-93.
 19. Tamura A, Fujioka T, Nasu M. Relation of *Helicobacter pylori* infection to plasma vitamin B12, folic acid and homocysteine levels in patients who underwent diagnostic coronary arteriography. *Am J Gastroenterol* 2002;97:861-6.
 20. Del Corral A, Carmel R. Transfer of cobalamin from the cobalamin-binding protein of egg yolk to R binder of human saliva and gastric juice. *Gastroenterology* 1990;98:1460-6.
 21. Shuval-Sudai O, Granot E. An association between *Helicobacter pylori* infection and serum vitamin B12 levels in healthy adults. *J Clin Gastroenterol* 2003;36:130-3.
 22. Appelmelk BJ, Simoons-Smit I, Negrini R, et al. Potential role of molecular mimicry between *Helicobacter pylori* lipopolysaccharide and host Lewis blood group antigens in autoimmunity. *Infect Immun* 1996;64:2031-40.
 23. Serin E, Gumurdulu Y, Ozer B, et al. Impact of *Helicobacter pylori* on the development of vitamin B12 deficiency in the absence of gastric atrophy. *Helicobacter* 2002;7:337-41.
 24. Harker LA, Slichter SL, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. *N Engl J Med* 1974;291:537-43.
 25. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. *J Clin Invest* 1976;57:1079-82.
 26. Genest JJ Jr, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. *J Am Coll Cardiol* 1990;16:1114-9.
 27. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. *Circulation* 1995;92:2825-30.
 28. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-57.
 29. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *J Am Coll Cardiol* 1996;27:517-27.
 30. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. *Annu Rev Med* 1998;49:31-62.
 31. Stamler JS, Osborne JA, Jaraki M, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. *Y Clin Invest* 1993;91:308-18.
 32. Harker LA, Harlan JM, Ross R. Effect of sulfapyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. *Circ Res* 1983;53:731-9.
 33. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. *Atherosclerosis* 1996;122:201-16.
 34. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. *J Clin Invest* 1976;58:731-41.
 35. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. *J Clin Invest* 1996;98:24-9.
 36. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiol: Superoxide-dependent and -independent mechanisms. *J Lipid Res* 1993;34:2051-61.
 37. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. *Circulation* 2003;107:398-404.
 38. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. *Arterioscler Thromb Vasc Biol* 1999;19:2348-54.
 39. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194-7.
 40. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? *Hypertension* 2004;44:6-11.
 41. Al-fawaeir S, Zaid MA. Serum levels of high sensitivity C-reactive protein in *H. pylori* infected patients. *J Invest Biochem* 2013;2:32-6.